SPP1 and neoplasm: The resulting SPP1+ myCAFs express and secrete high levels of SPP1, which engages integrin receptors on tumor cells and activates the ERK/MAPK pathway, thereby increasing resistance to antiandrogen therapies (e.g., enzalutamide, ENZ).